Proactive Investors - Run By Investors For Investors

Avacta Group PLC signs first significant pharmaceutical licensing deal

Alastair Smith, chief executive of Avacta Group PLC (LON:AVCT), discusses with Proactive London an Affimer therapeutics development partnership and license agreement that's been signed with LG Chem Life Sciences  - part of the South Korean LG Group.

Smith says it's a multi-target therapeutics development agreement which provides for upfront and near-term milestone payments, plus longer-term clinical development milestones totalling $180 million.

Meet West Wits Mining Limited, Global Energy Ventures Ltd, XTEK Ltd and ShareRoot Ltd at our event, Melbourne , 04 June 2019. Register here »
View full AVCT profile View Profile

Avacta Group PLC Timeline

CN Research
April 09 2019

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use